DGAP-News

GLOBAL BIOENERGIES REPORTS 2013 FINAL RESULTS

DGAP-News: Global Bioenergies S.A. / Key word(s): Final Results
GLOBAL BIOENERGIES REPORTS 2013 FINAL RESULTS

15.04.2014 / 19:21

---------------------------------------------------------------------

GLOBAL BIOENERGIES REPORTS
2013 FINANCIAL RESULTS

Evry (France), April 15th, 2014 - Global Bioenergies publishes audited
annual results for the fiscal year ended December 31st, 2013. The results
were validated by the Board of Directors on April 15th, 2014.
- Key results, December 31st, 2013

In EURK                                  from 01/01/13        from 01/01/12

                                        until 31/12/13       until 31/12/12

Revenues                                         1,180                1,977

Operating expenses                               7,849                5,367

Net profit/loss                                 -5,132               -2,420

In EURK                            As of Dec 31st 2013  As of Dec 31st 2012

Shareholder's Equity                            23,074                6,472

Cash and cash equivalents on hand               23,677                6,291

- Financial results and financial situation

The 1.2 million euros revenues result mainly from the strategic partnership
concluded with Synthos in 2011 for the development of a butadiene
bioproduction process.

Operating expenses amount to 7.8 million euros for the 2013 fiscal year.
The 46% growth compared to 2012 mainly results from the increase in staff
(from 37 employees on January 1st to 46 employees on December 31st) and
from the chemical engineering studies which prepare the industrialization
of the isobutene process.

The company cashed in 0.9 million euros of R&D tax credit ("Crédit d'Impôt
Recherche", or CIR) in August 2013 for the 2012 calendar year. R&D expenses
eligible for the 2013 CIR amounted to 4.7 million euros generating a 1.4
million euros CIR which should be cashed in Q3 2014.

As of December 31st, 2013, the net cash position amounts to 22.2 million
euros and the gross cash position to 23.7 million euros. The Company's only
bank debt is a 0.74 million euros interest free loan received from
Bpifrance (the French Public Investment Bank).

As of March 31st, 2014, the available gross cash position amounts to 21
million euros.

Liliane Bronstein, Chief Financial Officer of Global Bioenergies declares:
"In 2013 Global Bioenergies has further increased its efforts in R&D and
has intensified preparatory works in view of the installation of the
industrial pilots. A significant further growth of operating expenses is